JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, P. F.
Right arrow Articles by Barth, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, P. F.
Right arrow Articles by Barth, W. E.

Pirbuterol, a selecttve beta2 adrenergic bronchodilator

PF Moore, JW Constantine and WE Barth

Pirbuterol, 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert- butylaminoethyl)pyridine, is a new beta2 adrenergic agonist bronchodilator. Comparison of the relative potencies of pirbuterol, salbutamol and isoproterenol as relaxants of isolated guinea-pig tracheal muscle and as positive chronotropic agents in isolated guinea- pig atria indicate that the relative selectivity of pirbuterol for pulmonary as opposed to cardiac tissue is 9 times greater than that for salbutamol and some 1500 times greater than that for isoproterenol. Pirbuterol is effective by the oral, intravenous and inhalation routes of administration. In conscious guinea pigs, pirbuterol antagonizes both histamine- and acetylcholine-induced bronchoconstriction and "microshock" anaphylaxis; combinations of pirbuterol and theophylline cause additive effects against histamine-induced bronchoconstriction. In conscious dogs, the cardiovascular effects of pirbuterol are clearly distinguished from those of salbutamol, in that salbutamol causes a more pronounced tachycardia. In anesthetized dogs the cardiovascular effects of pirbuterol and salbutamol are comparable; they are less potent than isoproterenol and have less pronounced although longer lasting effects.

Volume 207, Issue 2, pp. 410-418, 11/01/1978
Copyright © 1978 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 CirculationHome page
Z. Ming, R. Parent, and M. Lavallee
ß2-Adrenergic Dilation of Resistance Coronary Vessels Involves KATP Channels and Nitric Oxide in Conscious Dogs
Circulation, March 18, 1997; 95(6): 1568 - 1576.
[Abstract] [Full Text]

Home page
 NEJMHome page
R. Matz, T. C. Chinet, D. Kinshuck, T. Malik, N. K. Mulleneisen, G. T. Ferguson, and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., September 23, 1993; 329(13): 967 - 968.
[Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics.